HRP20130202T1 - Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis - Google Patents

Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis Download PDF

Info

Publication number
HRP20130202T1
HRP20130202T1 HRP20130202AT HRP20130202T HRP20130202T1 HR P20130202 T1 HRP20130202 T1 HR P20130202T1 HR P20130202A T HRP20130202A T HR P20130202AT HR P20130202 T HRP20130202 T HR P20130202T HR P20130202 T1 HRP20130202 T1 HR P20130202T1
Authority
HR
Croatia
Prior art keywords
compound according
och3
halogen
alkyl
nhcor8
Prior art date
Application number
HRP20130202AT
Other languages
English (en)
Croatian (hr)
Inventor
Angus Macleod
Dale Robert Mitchell
Nicholas John Palmer
Christophe Claude Parsy
Michael Daniel Goldsmith
Clifford John Harris
Original Assignee
Biofocus Dpi Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofocus Dpi Limited filed Critical Biofocus Dpi Limited
Publication of HRP20130202T1 publication Critical patent/HRP20130202T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20130202AT 2007-08-21 2008-08-20 Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis HRP20130202T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716292.8A GB0716292D0 (en) 2007-08-21 2007-08-21 Imidazopyrazine compounds
PCT/EP2008/060896 WO2009024585A2 (en) 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis

Publications (1)

Publication Number Publication Date
HRP20130202T1 true HRP20130202T1 (hr) 2013-04-30

Family

ID=38566736

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130202AT HRP20130202T1 (hr) 2007-08-21 2008-08-20 Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis

Country Status (20)

Country Link
US (1) US8362018B2 (cg-RX-API-DMAC10.html)
EP (2) EP2567960A3 (cg-RX-API-DMAC10.html)
JP (1) JP2010536825A (cg-RX-API-DMAC10.html)
KR (1) KR20100081294A (cg-RX-API-DMAC10.html)
CN (1) CN101835780B (cg-RX-API-DMAC10.html)
AU (1) AU2008290531A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0815717A2 (cg-RX-API-DMAC10.html)
CA (1) CA2707521A1 (cg-RX-API-DMAC10.html)
CY (1) CY1113872T1 (cg-RX-API-DMAC10.html)
DK (1) DK2193131T3 (cg-RX-API-DMAC10.html)
ES (1) ES2404415T3 (cg-RX-API-DMAC10.html)
GB (1) GB0716292D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20130202T1 (cg-RX-API-DMAC10.html)
MX (1) MX2010001733A (cg-RX-API-DMAC10.html)
NZ (1) NZ584108A (cg-RX-API-DMAC10.html)
PL (1) PL2193131T3 (cg-RX-API-DMAC10.html)
PT (1) PT2193131E (cg-RX-API-DMAC10.html)
SI (1) SI2193131T1 (cg-RX-API-DMAC10.html)
WO (1) WO2009024585A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201002009B (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
PE20110854A1 (es) 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
AP2012006204A0 (en) 2009-10-21 2012-04-30 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists.
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
IN2012DN05081A (cg-RX-API-DMAC10.html) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
ES2551407T3 (es) * 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
CN103038235B (zh) 2010-06-01 2015-07-29 拜耳知识产权有限责任公司 取代的咪唑并吡嗪
CA2821829A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080228A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080232A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9284317B2 (en) * 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
GB201109763D0 (en) * 2011-06-10 2011-07-27 Ucl Business Plc Compounds
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
JPWO2013061962A1 (ja) * 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
BR112017023038A2 (pt) * 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
BR122023023802A2 (pt) 2015-04-29 2023-12-26 Janssen Pharmaceutica Nv Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem
CN107949563B (zh) * 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
JP6507976B2 (ja) * 2015-09-30 2019-05-08 東レ株式会社 イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
ES2995198T3 (en) 2016-01-05 2025-02-07 Incyte Corp Pyridine compounds as pi3k-gamma inhibitors
HK1250945A1 (zh) * 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
UY37381A (es) 2016-08-30 2018-03-23 Glaxosmithkline Ip No 2 Ltd Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
JP7133023B2 (ja) 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｉ４ｋｉｉｉベータ阻害剤
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN109369545B (zh) * 2018-12-14 2020-04-10 东营曜康医药科技有限公司 2-甲基-5-甲酸吡嗪的合成工艺
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
WO2021061803A1 (en) 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CN115667266A (zh) 2020-06-01 2023-01-31 豪夫迈·罗氏有限公司 新型咪唑并吡嗪衍生物
EP4161930A1 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Novel imidazo-pyrazine derivatives
CN113929633A (zh) * 2021-10-27 2022-01-14 山东大学 一种法匹拉韦的合成方法及其应用
CN113831255B (zh) * 2021-11-25 2022-03-11 山东诚创蓝海医药科技有限公司 一种2-氨基丙二酰胺的制备方法
CN115489188B (zh) * 2022-10-09 2023-08-29 安徽国风新材料股份有限公司 一种家居保护用聚酯薄膜及其制备方法
EP4623911A1 (en) 2024-03-25 2025-10-01 ETH Zurich Pi4kb inhibitors for the treatment of fatty liver disease
EP4623912A1 (en) 2024-03-25 2025-10-01 ETH Zurich A method for defattening a steatotic liver ex vivo

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) * 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
DK1296998T3 (da) 2000-05-23 2011-12-12 Univ Washington HCV-varianter
AU2002225895A1 (en) 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
ES2287074T3 (es) 2000-12-22 2007-12-16 Boehringer Ingelheim (Canada) Ltd. Molecula de rna autorreplicante del virus de la hepatitis c.
EP2050822B1 (en) 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C virus replicons and replicon enhanced cells
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
JP4799864B2 (ja) 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
AU2007200401A1 (en) * 2002-09-23 2007-02-22 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
DE602004024658D1 (de) 2003-02-13 2010-01-28 Merck & Co Inc Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
AR043002A1 (es) 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1945216A1 (en) 2005-11-10 2008-07-23 Schering Corporation Methods for inhibiting protein kinases
EP1945644A2 (en) 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008030795A2 (en) 2006-09-05 2008-03-13 Boards Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
US8268809B2 (en) * 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
PE20080931A1 (es) 2006-11-08 2008-07-19 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
US8243049B2 (en) 2006-12-20 2012-08-14 3M Innovative Properties Company Untethered stylus employing low current power converter
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds

Also Published As

Publication number Publication date
DK2193131T3 (da) 2013-04-22
WO2009024585A2 (en) 2009-02-26
NZ584108A (en) 2012-06-29
EP2193131B1 (en) 2013-01-30
BRPI0815717A2 (pt) 2015-02-10
MX2010001733A (es) 2010-07-06
ES2404415T3 (es) 2013-05-27
EP2567960A3 (en) 2013-06-05
ZA201002009B (en) 2010-12-29
US8362018B2 (en) 2013-01-29
GB0716292D0 (en) 2007-09-26
EP2193131A2 (en) 2010-06-09
HK1143810A1 (en) 2011-01-14
WO2009024585A3 (en) 2009-08-06
KR20100081294A (ko) 2010-07-14
PT2193131E (pt) 2013-04-04
US20110166147A1 (en) 2011-07-07
PL2193131T3 (pl) 2013-07-31
AU2008290531A1 (en) 2009-02-26
CN101835780A (zh) 2010-09-15
CA2707521A1 (en) 2009-02-26
SI2193131T1 (sl) 2013-06-28
EP2567960A2 (en) 2013-03-13
JP2010536825A (ja) 2010-12-02
CY1113872T1 (el) 2016-07-27
CN101835780B (zh) 2013-09-18

Similar Documents

Publication Publication Date Title
HRP20161103T1 (hr) Kemijski spojevi
HRP20100677T1 (hr) IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
ME02875B (me) Inhibitori hcv polimeraze
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
HRP20250386T1 (hr) Derivati piperidinil-indola za upotrebu u liječenju c3 glomerulopatije
HRP20140950T1 (hr) Novi spojevi i pripravci, te postupci njihove primjene
NZ591728A (en) Cephalosporin having catechol group
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
HRP20180483T1 (hr) Spoj kinolona
HRP20180081T1 (hr) Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
HRP20180196T1 (hr) Diketoni i hidroksiketoni kao aktivatori puta signalizacije katenina
HRP20171977T1 (hr) Derivati dolastatina 10 i auristatina
HRP20151075T1 (hr) Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat
HRP20170955T1 (hr) Derivati kinolin-8-sulfonamida s antikancerogenim djelovanjem
HRP20140223T2 (hr) Prolijekovi dolutegravir
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR064319A1 (es) Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros
CA2744756A1 (en) Monocarbams and their use as antibacterial agent
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections